MedTrace Logo

Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)

NCT04711356 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-12-13

Study results available
· View outcomes & findings →

Summary

This is an open-label study evaluating the safety and immunogenicity of a booster dose of Ad26.ZEBOV administered to children who were previously vaccinated with Ad26.ZEBOV followed by MVA-BN-Filo 56 days later.

Conditions

  • Ebola Virus Disease

Interventions

DRUG

Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection

Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein

Sponsors & Collaborators

  • Innovative Medicines Initiative

    collaborator OTHER

  • University of Sierra Leone

    collaborator OTHER

  • London School of Hygiene and Tropical Medicine

    lead OTHER

Principal Investigators

  • Deborah Watson-Jones, PhD · London School of Hygiene and Tropical Medicine

  • Bailah Leigh, MD · University of Sierra Leone

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-08
Primary Completion
2021-09-17
Completion
2022-03-31

Countries

  • Sierra Leone

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04711356 on ClinicalTrials.gov